Anti-platelet therapy with clopidogrel (Plavix) and aspirin is the standard of care for secondary prevention of myocardial Infarction. Despite its widespread use, 4 - 32% of Individuals are not responsive to clopidogrel. This renewal application will build upon significant progress made during the initial funding period in which we completed the Amish Pharmacogenomics of Anti-platelet lnterventlon-1 (PAPI-1) Study. Through the first genome-wide association study (GWAS) of its kind, we found that the loss of function cytochrome P450 2C19*2 (CYP2C19*2) variant is a major determinant of clopidogrel response, accounting for 12% of the variation in response. In an Independent cohort, we found that ~30% of the general population harboring CYP2C19*2 have poorer platelet response to clopidogrel and are at a 2.4-fold higher risk of having an ischemic cardiac event or death. The overall goal of this renewal application is to continue to advance the science of anti-platelet pharmacogenomics and its clinical translation. We hypothesize (a) CYP2C19 genotype-directed anti-platelet therapy will be superior to standard of care therapy;and (b) the genetic architecture of clopidogrel response Includes common and rare variants in yet-to-be identified genes. We have amassed a team of multidisciplinary investigators and collaborators and will capitalize on synergies created by active participation in the Pharmacogenomics Research Network to address the following Specific Alms: (1) To conduct the PAPI-2 Study, a prospective multicenter randomized double-blind clinical trial comparing cardiovascular events using CYP2C19 genotype-directed versus standard of care anti-platelet therapy in over 2000 patients with coronary heart disease;(2) To identify common variants in novel genes and loci for clopidogrel response by performing a large GWAS as part of a new Clopidogrel Pharmacogenomics GWAS Consortium;and (3) To identify rare variants in genes previously not known to influence platelet function or clopidogrel response by performing genome-wide exon (exome) sequencing from the extremes of the distribution of clopidogrel response.

Public Health Relevance

The proposed randomized clinical trial will provide the evidence base for translation of genotype-directed anti-platelet therapy into clinical practice. The Identification of common and rare variants in novel genes for clopidogrel response will provide new insights into platelet biology and variation in anti-platelet therapy response, and potentially, new targets for more effective agents to prevent and treat CHD.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-GGG-M (52))
Program Officer
Jaquish, Cashell E
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Maryland Baltimore
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Sweet, K; Sturm, A C; Schmidlen, T et al. (2016) EMR documentation of physician-patient communication following genomic counseling for actionable complex disease and pharmacogenomic results. Clin Genet :
Gammal, R S; Court, M H; Haidar, C E et al. (2016) Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing. Clin Pharmacol Ther 99:363-9
Weitzel, Kristin Wiisanen; McDonough, Caitrin W; Elsey, Amanda R et al. (2016) Effects of Using Personal Genotype Data on Student Learning and Attitudes in a Pharmacogenomics Course. Am J Pharm Educ 80:122
Peterson, J F; Field, J R; Unertl, K M et al. (2016) Physician response to implementation of genotype-tailored antiplatelet therapy. Clin Pharmacol Ther 100:67-74
Schmidlen, Tara J; Scheinfeldt, Laura; Zhaoyang, Ruixue et al. (2016) Genetic Knowledge Among Participants in the Coriell Personalized Medicine Collaborative. J Genet Couns 25:385-94
O'Donnell, P H; Danahey, K; Ratain, M J (2016) The Outlier in All of Us: Why Implementing Pharmacogenomics Could Matter for Everyone. Clin Pharmacol Ther 99:401-4
Cutting, Elizabeth; Banchero, Meghan; Beitelshees, Amber L et al. (2016) User-centered design of multi-gene sequencing panel reports for clinicians. J Biomed Inform 63:1-10
Wang, Hong; Hong, Chan E; Lewis, Joshua P et al. (2016) Effect of Two Lipoprotein (a)-Associated Genetic Variants on Plasminogen Levels and Fibrinolysis. G3 (Bethesda) :
Peterson, J F; Field, J R; Shi, Y et al. (2016) Attitudes of clinicians following large-scale pharmacogenomics implementation. Pharmacogenomics J 16:393-8
Saito, Y; Stamp, L K; Caudle, K E et al. (2016) Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update. Clin Pharmacol Ther 99:36-7

Showing the most recent 10 out of 71 publications